“…But for RRS methods, many differences between techniques are minor, often implementing streamlined library preparation and cost reduction (e.g., GGRS (Chen et al., ), ezRAD (Toonen et al., )) or the use of specific restriction enzymes and adaptors designed to optimize sequencing depth, coverage, and multiplexing capacity (e.g., MSG (Andolfatto et al., ); two‐enzyme GBS (Poland et al., ); SLAF‐seq (Sun et al., ); quaddRAD (Franchini et al., )). Thus, many published methods, although prone to distinct biases or technical difficulties and subject to a myriad of downstream bioinformatic considerations (Flanagan & Jones, ; Van Dijk, Jaszczyszyn, & Thermes, ), arguably do not meet proposed criteria for publication with a unique name (e.g., NUAP, ). The recently upheld US KeyGene patent covering these methods also seems to suggest that, from a legal standpoint, they are not significantly different from one another (U.S. Patent 8,815,512 B2).…”